公开(公告)号：US20150190369A1

公开(公告)日：2015-07-09

申请号：US14410774

申请日：2013-06-28

申请人： Majambu Mbikay ,  Francine Sirois ,  Michel Chretien ,  Janice Mayne

发明人： Majambu Mbikay ,  Francine Sirois ,  Michel Chretien ,  Janice Mayne

IPC分类号： A61K31/366 ,  A61K31/7048

CPC分类号： A61K31/366 ,  A61K31/7048 ,  A61K45/06 ,  A61K2300/00

摘要： There is described herein a use of quercetin-3-O-β-D-glucoside (Q3G) for increasing the amount of cell surface low-density lipoprotein receptor (LDLR) on a cell and for reducing the amount of functional proprotein convertase subtilisin/kexin type 9 (PCSK9) secreted by the cell, where the Q3G is formulated for administration to the cell, and where the increase in cell surface LDLR and the decrease in secretion of functional PCSK9 is in comparison to the cell not exposed to Q3G. The use may optionally include the treatment of a statin. There is also described a method of reducing plasma cholesterol levels in a patient in need thereof. The method includes treating the patient with a therapeutically effective amount of Q3G and, optionally, a therapeutically effective amount of a statin.

摘要翻译： 本文描述了槲皮素-3-O-和bgr-D-葡萄糖苷（Q3G）用于增加细胞上的细胞表面低密度脂蛋白受体（LDLR）的量并减少功能性前体蛋白转化酶枯草杆菌蛋白酶的量 由细胞分泌的kKin 9型（PCSK9），其中Q3G配制用于给细胞，并且其中细胞表面LDLR的增加和功能性PCSK9的分泌减少与未暴露于Q3G的细胞相比。 使用可以任选地包括他汀类药物的治疗。 还描述了在有需要的患者中降低血浆胆固醇水平的方法。 该方法包括用治疗有效量的Q3G和任选的治疗有效量的他汀类药物治疗患者。